These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 29050547)
1. Editorial: Development of Anticancer Reagents. Liu X Comb Chem High Throughput Screen; 2017; 20(5):356. PubMed ID: 29050547 [No Abstract] [Full Text] [Related]
3. Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. Shah AY; Gao J; Siefker-Radtke AO Immunotherapy; 2017 Sep; 9(10):781-784. PubMed ID: 28877627 [No Abstract] [Full Text] [Related]
4. Immunotherapy: Immune-modified response criteria - an iterative learning process? Ott PA Nat Rev Clin Oncol; 2018 May; 15(5):267-268. PubMed ID: 29532797 [No Abstract] [Full Text] [Related]
5. Part II: Checkpoint inhibitors in cancer therapy. Daud AI Immunotherapy; 2016 Jun; 8(7):761-2. PubMed ID: 27349974 [No Abstract] [Full Text] [Related]
8. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717 [TBL] [Abstract][Full Text] [Related]
9. Part I: Checkpoint inhibitors in cancer therapy. Daud AI Immunotherapy; 2016 Jun; 8(6):675-6. PubMed ID: 27197535 [No Abstract] [Full Text] [Related]
10. Introduction: Cancer Immunology Special Issue-Immunotherapy. Kawakami Y Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100 [No Abstract] [Full Text] [Related]
11. Immunotherapy: pembrolizumab-is the writing on the wall for cancer? Hutchinson L Nat Rev Clin Oncol; 2015 Jul; 12(7):371. PubMed ID: 25963092 [No Abstract] [Full Text] [Related]
12. [Strategies around PD-L1 testing in France]. Penault-Llorca F Ann Pathol; 2017 Feb; 37(1):3-4. PubMed ID: 28108043 [No Abstract] [Full Text] [Related]
14. Therapeutics: Spoilt for choice. Eisenstein M Nature; 2017 Nov; 551(7679):S36-S38. PubMed ID: 29117155 [No Abstract] [Full Text] [Related]
15. Emerging biomarkers for PD-1 pathway cancer therapy. Lim JS; Sundar R; Chénard-Poirier M; Lopez J; Yap TA Biomark Med; 2017 Jan; 11(1):53-67. PubMed ID: 27936870 [TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy in patients with preexisting autoimmune disorders. Donia M; Pedersen M; Svane IM Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287 [TBL] [Abstract][Full Text] [Related]
17. A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma. Hsu FS; Su CH; Huang KH J Immunol Res; 2017; 2017():6940546. PubMed ID: 29376081 [TBL] [Abstract][Full Text] [Related]
18. Regulatory mechanisms of PD-L1 expression in cancer cells. Shi Y Cancer Immunol Immunother; 2018 Oct; 67(10):1481-1489. PubMed ID: 30120503 [TBL] [Abstract][Full Text] [Related]
19. Which checkpoint inhibitor? An embarrassment of riches for bladder cancer. Gill DM; Sonpavde G; Pal SK; Agarwal N Immunotherapy; 2017 May; 9(6):463-466. PubMed ID: 28472906 [No Abstract] [Full Text] [Related]
20. PD-1/PD-L1 Pathway in Breast Cancer. Schütz F; Stefanovic S; Mayer L; von Au A; Domschke C; Sohn C Oncol Res Treat; 2017; 40(5):294-297. PubMed ID: 28346916 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]